Diabetes impairs hematopoietic stem cell mobilization by altering niche function

Francesca Ferraro, Stefania Lymperi, Simón Méndez-Ferrer, Borja Saez, Joel A. Spencer, Beow Y. Yeap, Elena Masselli, Gallia Graiani, Lucia Prezioso, Elisa Lodi Rizzini, Marcellina Mangoni, Vittorio Rizzoli, Stephen M. Sykes, Charles P. Lin, Paul S. Frenette, Federico Quaini, David T. Scadden

Research output: Contribution to journalArticle

171 Citations (Scopus)

Abstract

Success with transplantation of autologous hematopoietic stem and progenitor cells (HSPCs) in patients depends on adequate collection of these cells after mobilization from the bone marrow niche by the cytokine granulocyte colony-stimulating factor (G-CSF). However, some patients fail to achieve sufficient HSPC mobilization. Retrospective analysis of bone marrow transplant patient records revealed that diabetes correlated with poor mobilization of CD34+ HSPCs. Inmouse models of type 1 and type 2 diabetes (streptozotocin-induced and db/db mice, respectively), we found impaired egress of murine HSPCs from the bone marrow after G-CSF treatment. Furthermore, HSPCs were aberrantly localized in the marrow niche of the diabetic mice, and abnormalities in the number and function of sympathetic nerve termini were associated with this mislocalization. Aberrant responses to β-adrenergic stimulation of the bone marrow included an inability of marrow mesenchymal stem cells expressing the marker nestin to downmodulate the chemokine CXCL12 in response to G-CSF treatment (mesenchymal stem cells are reported to be critical for HSPC mobilization). The HSPC mobilization defect was rescued by direct pharmacological inhibition of the interaction of CXCL12 with its receptor CXCR4 using the drug AMD3100. These data suggest that there are diabetesinduced changes in bone marrow physiology and microanatomy and point to a potential intervention to overcome poor HSPC mobilization in diabetic patients.

Original languageEnglish (US)
JournalScience Translational Medicine
Volume3
Issue number104
DOIs
StatePublished - Oct 12 2011

Fingerprint

Hematopoietic Stem Cell Mobilization
Hematopoietic Stem Cells
Bone Marrow
Granulocyte Colony-Stimulating Factor
Mesenchymal Stromal Cells
CXCR4 Receptors
Chemokine CXCL12
Nestin
Autologous Transplantation
Streptozocin
Type 1 Diabetes Mellitus
Adrenergic Agents
Type 2 Diabetes Mellitus

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ferraro, F., Lymperi, S., Méndez-Ferrer, S., Saez, B., Spencer, J. A., Yeap, B. Y., ... Scadden, D. T. (2011). Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Science Translational Medicine, 3(104). https://doi.org/10.1126/scitranslmed.3002191

Diabetes impairs hematopoietic stem cell mobilization by altering niche function. / Ferraro, Francesca; Lymperi, Stefania; Méndez-Ferrer, Simón; Saez, Borja; Spencer, Joel A.; Yeap, Beow Y.; Masselli, Elena; Graiani, Gallia; Prezioso, Lucia; Rizzini, Elisa Lodi; Mangoni, Marcellina; Rizzoli, Vittorio; Sykes, Stephen M.; Lin, Charles P.; Frenette, Paul S.; Quaini, Federico; Scadden, David T.

In: Science Translational Medicine, Vol. 3, No. 104, 12.10.2011.

Research output: Contribution to journalArticle

Ferraro, F, Lymperi, S, Méndez-Ferrer, S, Saez, B, Spencer, JA, Yeap, BY, Masselli, E, Graiani, G, Prezioso, L, Rizzini, EL, Mangoni, M, Rizzoli, V, Sykes, SM, Lin, CP, Frenette, PS, Quaini, F & Scadden, DT 2011, 'Diabetes impairs hematopoietic stem cell mobilization by altering niche function', Science Translational Medicine, vol. 3, no. 104. https://doi.org/10.1126/scitranslmed.3002191
Ferraro, Francesca ; Lymperi, Stefania ; Méndez-Ferrer, Simón ; Saez, Borja ; Spencer, Joel A. ; Yeap, Beow Y. ; Masselli, Elena ; Graiani, Gallia ; Prezioso, Lucia ; Rizzini, Elisa Lodi ; Mangoni, Marcellina ; Rizzoli, Vittorio ; Sykes, Stephen M. ; Lin, Charles P. ; Frenette, Paul S. ; Quaini, Federico ; Scadden, David T. / Diabetes impairs hematopoietic stem cell mobilization by altering niche function. In: Science Translational Medicine. 2011 ; Vol. 3, No. 104.
@article{e5e6ea947ada46dfaa76205d664906b8,
title = "Diabetes impairs hematopoietic stem cell mobilization by altering niche function",
abstract = "Success with transplantation of autologous hematopoietic stem and progenitor cells (HSPCs) in patients depends on adequate collection of these cells after mobilization from the bone marrow niche by the cytokine granulocyte colony-stimulating factor (G-CSF). However, some patients fail to achieve sufficient HSPC mobilization. Retrospective analysis of bone marrow transplant patient records revealed that diabetes correlated with poor mobilization of CD34+ HSPCs. Inmouse models of type 1 and type 2 diabetes (streptozotocin-induced and db/db mice, respectively), we found impaired egress of murine HSPCs from the bone marrow after G-CSF treatment. Furthermore, HSPCs were aberrantly localized in the marrow niche of the diabetic mice, and abnormalities in the number and function of sympathetic nerve termini were associated with this mislocalization. Aberrant responses to β-adrenergic stimulation of the bone marrow included an inability of marrow mesenchymal stem cells expressing the marker nestin to downmodulate the chemokine CXCL12 in response to G-CSF treatment (mesenchymal stem cells are reported to be critical for HSPC mobilization). The HSPC mobilization defect was rescued by direct pharmacological inhibition of the interaction of CXCL12 with its receptor CXCR4 using the drug AMD3100. These data suggest that there are diabetesinduced changes in bone marrow physiology and microanatomy and point to a potential intervention to overcome poor HSPC mobilization in diabetic patients.",
author = "Francesca Ferraro and Stefania Lymperi and Sim{\'o}n M{\'e}ndez-Ferrer and Borja Saez and Spencer, {Joel A.} and Yeap, {Beow Y.} and Elena Masselli and Gallia Graiani and Lucia Prezioso and Rizzini, {Elisa Lodi} and Marcellina Mangoni and Vittorio Rizzoli and Sykes, {Stephen M.} and Lin, {Charles P.} and Frenette, {Paul S.} and Federico Quaini and Scadden, {David T.}",
year = "2011",
month = "10",
day = "12",
doi = "10.1126/scitranslmed.3002191",
language = "English (US)",
volume = "3",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "104",

}

TY - JOUR

T1 - Diabetes impairs hematopoietic stem cell mobilization by altering niche function

AU - Ferraro, Francesca

AU - Lymperi, Stefania

AU - Méndez-Ferrer, Simón

AU - Saez, Borja

AU - Spencer, Joel A.

AU - Yeap, Beow Y.

AU - Masselli, Elena

AU - Graiani, Gallia

AU - Prezioso, Lucia

AU - Rizzini, Elisa Lodi

AU - Mangoni, Marcellina

AU - Rizzoli, Vittorio

AU - Sykes, Stephen M.

AU - Lin, Charles P.

AU - Frenette, Paul S.

AU - Quaini, Federico

AU - Scadden, David T.

PY - 2011/10/12

Y1 - 2011/10/12

N2 - Success with transplantation of autologous hematopoietic stem and progenitor cells (HSPCs) in patients depends on adequate collection of these cells after mobilization from the bone marrow niche by the cytokine granulocyte colony-stimulating factor (G-CSF). However, some patients fail to achieve sufficient HSPC mobilization. Retrospective analysis of bone marrow transplant patient records revealed that diabetes correlated with poor mobilization of CD34+ HSPCs. Inmouse models of type 1 and type 2 diabetes (streptozotocin-induced and db/db mice, respectively), we found impaired egress of murine HSPCs from the bone marrow after G-CSF treatment. Furthermore, HSPCs were aberrantly localized in the marrow niche of the diabetic mice, and abnormalities in the number and function of sympathetic nerve termini were associated with this mislocalization. Aberrant responses to β-adrenergic stimulation of the bone marrow included an inability of marrow mesenchymal stem cells expressing the marker nestin to downmodulate the chemokine CXCL12 in response to G-CSF treatment (mesenchymal stem cells are reported to be critical for HSPC mobilization). The HSPC mobilization defect was rescued by direct pharmacological inhibition of the interaction of CXCL12 with its receptor CXCR4 using the drug AMD3100. These data suggest that there are diabetesinduced changes in bone marrow physiology and microanatomy and point to a potential intervention to overcome poor HSPC mobilization in diabetic patients.

AB - Success with transplantation of autologous hematopoietic stem and progenitor cells (HSPCs) in patients depends on adequate collection of these cells after mobilization from the bone marrow niche by the cytokine granulocyte colony-stimulating factor (G-CSF). However, some patients fail to achieve sufficient HSPC mobilization. Retrospective analysis of bone marrow transplant patient records revealed that diabetes correlated with poor mobilization of CD34+ HSPCs. Inmouse models of type 1 and type 2 diabetes (streptozotocin-induced and db/db mice, respectively), we found impaired egress of murine HSPCs from the bone marrow after G-CSF treatment. Furthermore, HSPCs were aberrantly localized in the marrow niche of the diabetic mice, and abnormalities in the number and function of sympathetic nerve termini were associated with this mislocalization. Aberrant responses to β-adrenergic stimulation of the bone marrow included an inability of marrow mesenchymal stem cells expressing the marker nestin to downmodulate the chemokine CXCL12 in response to G-CSF treatment (mesenchymal stem cells are reported to be critical for HSPC mobilization). The HSPC mobilization defect was rescued by direct pharmacological inhibition of the interaction of CXCL12 with its receptor CXCR4 using the drug AMD3100. These data suggest that there are diabetesinduced changes in bone marrow physiology and microanatomy and point to a potential intervention to overcome poor HSPC mobilization in diabetic patients.

UR - http://www.scopus.com/inward/record.url?scp=80054035544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054035544&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3002191

DO - 10.1126/scitranslmed.3002191

M3 - Article

C2 - 21998408

AN - SCOPUS:80054035544

VL - 3

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 104

ER -